Hasten Pharmaceutical

Hasten Pharmaceutical, established in 2020, operates as a specialized entity integrating R&D, production, and commercial promotion within the pharmaceutical and healthcare sectors. The company maintains a comprehensive industry chain, supported by strategic investments from Cambridge Capital, Hefei Industrial Investment Group, and the Hefei City Feidong County government. Its business operations span across China, focusing on innovation-driven biopharmaceutical solutions that address complex disease areas. The firm leverages its unique position to bridge the gap between early-stage biotech research and large-scale commercial distribution.

The organization currently employs 500-1,000 employees and manages 7 distinct locations to support its operational footprint. Hasten Pharmaceutical specializes in critical care and biopharmaceutical product development, addressing unmet medical needs through advanced biotech research and clinical innovation. Meet Hasten Pharmaceutical's team to understand the leadership driving these innovation-focused initiatives and the organizational structure supporting their R&D pipeline. The team is dedicated to maintaining high standards in pharmaceutical manufacturing and regulatory compliance across all regional facilities.

With a robust financial foundation, the company recently secured $315.0M in funding during an April 2023 financing round led by Mubadala and CBC Group. Hasten Pharmaceutical reports annual revenue of $19.9M, reflecting its growth trajectory in the competitive Chinese healthcare market. Explore financial highlights to review detailed metrics regarding their capital structure, investment history, and fiscal performance. This financial stability enables the company to continue its aggressive expansion and investment in next-generation therapeutic technologies.